OUR STRATEGY

At Intarcia, through the passion and commitment of our employees, we seek to leverage our technologies in drug development and delivery to provide improved therapeutic outcomes for patients and to help patients achieve a better quality of life.

One of the biggest problems in the treatment of chronic disease is that at least half of patients lack effective control of their condition due to the sub-optimal effectiveness of their medication in the ‘real-world’ circumstances in which they must be taken: patients living at home who are on their own to follow the prescribing instructions for their medications. Unfortunately, after just three-to-six months, the majority of patients with chronic conditions stop taking their pills and injections as prescribed by their doctor. We aim to address this widespread and serious problem in chronic disease by introducing a new way to deliver therapies continuously and consistently for very extended periods of time. By doing so, our advanced drug delivery system has the potential to deliver game-changing improvement in medication adherence over time, promising to break the long-standing and costly barrier to greater efficacy and better long-term outcomes in chronic disease management.

Our novel technology platform, the Medici Drug Delivery System, is a proprietary subcutaneous delivery system comprised of three unique technologies:

  • A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures for up to three years or more
  • A matchstick-sized osmotic mini-pump that is placed just under the dermal layer of skin to deliver a continuous and consistent flow of medication
  • A placement technology including proprietary tools designed to provide an optimal user experience

Once a drug is approved, a trained healthcare professional can place the small device in an in-office procedure. Once in place under the skin, water from the extracellular fluid enters the pump device at one end – by diffusing through a semi-permeable membrane directly into an osmotic engine – that expands to drive a piston at a controlled rate. This allows the drug within the pump to be released in a steady, consistent fashion at the other end of the device. Each osmotic mini-pump is designed to hold an appropriate volume of drug to treat a patient for up to a full year.

Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic, serious disorders such as diabetes, obesity, autoimmune, and other serious diseases.

Developing Products with Significant Market Potential

Intarcia strives to develop product candidates with a demonstrated potential to deliver significant therapeutic improvements over existing therapies. We focus on therapies that address significant unmet medical needs and represent large commercial opportunities. The therapies we are developing:

  • Are based on promising therapeutic classes with proven clinical safety and activity;
  • Hold potential to represent significant improvements over the established standards of care;
  • May qualify for accelerated development and regulatory pathways; and
  • Create proprietary product candidates, securing or extending exclusivity.

By targeting product candidates from proven therapeutic classes and existing safety and clinical data, our development approach allows us to mitigate risks while reducing the cost and time required for developing products. If we are able to complete product development with fewer clinical trials than are required for a new therapeutic, we may have lower development costs and shorter timelines. By delivering these product candidates facilitated by Intarcia's Medici Drug Delivery System, we strive to deliver therapy with a truly optimized therapeutic index.

Maximizing Commercial Potential of The Medici Drug Delivery System

Medici

Based on the successful completion of Phase 3 clinical trials for ITCA 650, Intarcia’s investigational therapy in type 2 diabetes, we continue to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:

  • Evaluation of new applications of the Medici Drug Delivery System to develop products for which we can hold exclusive development and commercialization rights; and
  • Exploration of collaborative opportunities with partners to which our formulation and drug delivery technology and expertise can lend enhancement of life-cycle management, product line extension or a competitive edge.

To discuss opportunities, please contact our business development and licensing office at busdev@intarcia.com.

Our Vision

Unleashing talent to deliver disruptively innovative and life-changing medicines that transform business models, standards of care, and outcomes for patients, payers and providers.




Pipeline News

Intarcia Acquires Phoundry Pharmaceuticals
Acquisition of world class peptide team and library of optimized peptide assets creates opportunity for "NextGen" ITCA 650 combo therapy targeting diabetes and obesity. Other important diseases to be explored for mid and long-term pipeline.


Intarcia and Numab Sign Multi-Asset Collaboration to Develop Once-Yearly Therapies
Collaboration combines Intarcia’s proprietary delivery technologies with Numab’s novel multi-specific antibody technology.